Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | TSPO | P30536 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GUSB | P08236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093239 | 0.77 | MAPT (0.42) | KMT2ACTSAMEN1ALDH1A1 | |
| SCHEMBL5099932 | 0.77 | MAPK14 (0.46) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL5093365 | 0.73 | MAPK14 (0.44) | KMT2ACTSAMEN1ALDH1A1NPSR1 | |
| SCHEMBL3048277 | 0.69 | ACP3 (0.59) | KMT2AECE1MEN1CYP2C9ALDH1A1 | |
| SCHEMBL9201734 | 0.68 | RXRA (0.46) | — | |
| SCHEMBL6366676 | 0.66 | CYP2C9 (0.49) | ECE1CYP2C9ALDH1A1 | |
| SCHEMBL6366679 | 0.66 | CYP2C9 (0.49) | ECE1CYP2C9ALDH1A1 | |
| SCHEMBL1863359 | 0.66 | CYP2C9 (0.49) | ECE1CYP2C9ALDH1A1 | |
| SCHEMBL6743921 | 0.65 | CYP2C9 (0.59) | KMT2AECE1MEN1CYP2C9TSHR | |
| SCHEMBL22614679 | 0.65 | ROCK2 (0.52) | ECE1CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | claimed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | claimed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | claimed |
| US-20050197377-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-09-08 | — | — | US | claimed |
| WO-2005063716-A1 | IMIDAZOLES AND THEIR USE CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-14 | — | — | WO | claimed |
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | disclosed |
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | disclosed |
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | disclosed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-20050197377-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005063716-A1 | IMIDAZOLES AND THEIR USE CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197377-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GIPR | KMT2A 4359/4885ECE1 902/4885CTSA 2761/4885 |
| US-20070249698-A1 | CCK-1 Receptor Modulators | CCKAR, CCKBR, GIPR | KMT2A 4359/4885ECE1 902/4885CTSA 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.